Major Pharma Companies and CROs Surveyed Have Adopted Digital Pathology

The “2023 Life Sciences Digital Pathology Adoption Survey” asked 40 senior executives from top pharmaceutical companies and leading contract research organizations (CROs) about their use of digital pathology, the benefits it has delivered, and its future impacts. The results collectively indicate a growing need to unify teams, applications, including AI, and pathology data with a modern software platform that drives all stages of R&D across the connected enterprise.